BlackRock Inc. grew its holdings in shares of Inogen Inc (NASDAQ:INGN) by 4.4% during the fourth quarter, according to its most recent 13F filing with the SEC. The institutional investor owned 2,233,303 shares of the medical technology company’s stock after buying an additional 93,873 shares during the period. BlackRock Inc. owned approximately 10.46% of Inogen worth $277,307,000 as of its most recent filing with the SEC.

Other institutional investors have also bought and sold shares of the company. Zurcher Kantonalbank Zurich Cantonalbank lifted its holdings in shares of Inogen by 9.6% in the 4th quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 1,276 shares of the medical technology company’s stock worth $158,000 after purchasing an additional 112 shares in the last quarter. WINTON GROUP Ltd lifted its holdings in shares of Inogen by 5.8% in the 4th quarter. WINTON GROUP Ltd now owns 4,506 shares of the medical technology company’s stock worth $560,000 after purchasing an additional 249 shares in the last quarter. PNC Financial Services Group Inc. lifted its holdings in shares of Inogen by 30.2% in the 4th quarter. PNC Financial Services Group Inc. now owns 1,113 shares of the medical technology company’s stock worth $138,000 after purchasing an additional 258 shares in the last quarter. Sapphire Star Partners LP lifted its holdings in shares of Inogen by 5.6% in the 3rd quarter. Sapphire Star Partners LP now owns 7,301 shares of the medical technology company’s stock worth $1,783,000 after purchasing an additional 385 shares in the last quarter. Finally, SG Americas Securities LLC lifted its holdings in shares of Inogen by 6.1% in the 4th quarter. SG Americas Securities LLC now owns 8,368 shares of the medical technology company’s stock worth $1,039,000 after purchasing an additional 479 shares in the last quarter. Hedge funds and other institutional investors own 98.63% of the company’s stock.

A number of brokerages recently issued reports on INGN. Zacks Investment Research upgraded Inogen from a “hold” rating to a “buy” rating and set a $169.00 target price on the stock in a report on Tuesday, February 5th. BidaskClub upgraded Inogen from a “strong sell” rating to a “sell” rating in a report on Wednesday, November 28th. Piper Jaffray Companies cut their target price on Inogen from $290.00 to $185.00 and set an “overweight” rating on the stock in a report on Wednesday, February 27th. JPMorgan Chase & Co. cut their target price on Inogen to $175.00 and set an “overweight” rating on the stock in a report on Wednesday, February 27th. Finally, Needham & Company LLC reiterated a “strong-buy” rating and issued a $191.00 target price (down from $280.00) on shares of Inogen in a report on Wednesday, February 27th. Two equities research analysts have rated the stock with a sell rating, two have issued a hold rating, four have assigned a buy rating and one has assigned a strong buy rating to the company. Inogen presently has a consensus rating of “Hold” and a consensus target price of $189.00.

In related news, Director Raymond Huggenberger sold 8,500 shares of the stock in a transaction on Tuesday, January 15th. The stock was sold at an average price of $136.81, for a total value of $1,162,885.00. Following the completion of the sale, the director now directly owns 11,297 shares of the company’s stock, valued at approximately $1,545,542.57. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link. Corporate insiders own 5.29% of the company’s stock.

NASDAQ INGN opened at $96.38 on Friday. The firm has a market capitalization of $2.09 billion, a P/E ratio of 41.90, a P/E/G ratio of 3.17 and a beta of 1.51. Inogen Inc has a 12 month low of $91.90 and a 12 month high of $287.79.

Inogen (NASDAQ:INGN) last released its quarterly earnings results on Tuesday, February 26th. The medical technology company reported $0.44 EPS for the quarter, beating analysts’ consensus estimates of $0.25 by $0.19. The business had revenue of $86.50 million during the quarter, compared to analyst estimates of $82.06 million. Inogen had a return on equity of 18.60% and a net margin of 14.48%. Inogen’s quarterly revenue was up 35.6% compared to the same quarter last year. During the same period in the prior year, the firm posted ($0.03) EPS. As a group, equities analysts anticipate that Inogen Inc will post 1.95 earnings per share for the current fiscal year.

ILLEGAL ACTIVITY WARNING: “Inogen Inc (INGN) Shares Bought by BlackRock Inc.” was first published by The Cerbat Gem and is owned by of The Cerbat Gem. If you are viewing this piece on another publication, it was stolen and reposted in violation of U.S. and international copyright and trademark laws. The original version of this piece can be viewed at https://www.thecerbatgem.com/2019/03/15/inogen-inc-ingn-shares-bought-by-blackrock-inc.html.

Inogen Profile

Inogen, Inc, a medical technology company, primarily develops, manufactures, and markets portable oxygen concentrators for patients, physicians and other clinicians, and third-party payors in the United States and internationally. Its oxygen concentrators are used to deliver supplemental long-term oxygen therapy to patients suffering from chronic respiratory conditions.

See Also: Diversification Important in Investing

Institutional Ownership by Quarter for Inogen (NASDAQ:INGN)

Receive News & Ratings for Inogen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Inogen and related companies with MarketBeat.com's FREE daily email newsletter.